Neuron23 Secures $2.5 Million Grant from The Michael J. Fox Foundation to Expand Precision Medicine Parkinson’s Trial into Israel Neuron23 Inc., a clinical-stage biotechnology company focused on advancing precision medicine approaches for Parkinson’s disease, has received a $2.5 million grant…
Deciphera Pharmaceuticals Launches Global Phase 3 INTREPID Trial of Sapablursen for Polycythemia Vera Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd., has announced a significant milestone in the development of a potential new treatment for polycythemia vera (PV), with…
Jazz Pharmaceuticals and AbCellera Partner to Advance Next-Generation T-Cell Engaging Antibodies for Gastrointestinal and Solid Tumors Jazz Pharmaceuticals and AbCellera have entered into a strategic research collaboration aimed at discovering and developing a new generation of T-cell engaging (TCE) multispecific…
Senopsys Celebrates 20 Years of Advancing Patient-Friendly Medicines Through Sensory Science Senopsys, a company recognized for its expertise in sensory science and pharmaceutical palatability solutions, is marking its 20th anniversary of serving the global biopharmaceutical industry. Over the past two…
Fujifilm and HORIBA Co-Develop High-Sensitivity Inline Raman Measurement System to Advance Biopharmaceutical Manufacturing FUJIFILM Corporation and HORIBA, Ltd. have announced the joint development of a high-sensitivity inline Raman measurement system designed to provide continuous, real-time monitoring of critical manufacturing parameters…
Incyte Reports Positive Phase 3 frontMIND Results Showing Tafasitamab and Lenalidomide Plus R-CHOP Improves Outcomes in High-Risk DLBCL and HGBL Incyte has announced positive results from its pivotal Phase 3 frontMIND clinical trial, demonstrating that the addition of tafasitamab and…
Biocytogen’s Boston Research Facility Earns AAALAC International Full Accreditation, Reinforcing Commitment to Scientific Excellence and Animal Welfare Biocytogen has announced a significant achievement for its U.S. research operations, revealing that its Boston research facility has been awarded Full Accreditation by…
Arialys Therapeutics Advances ART5803 Development With Phase 2 Progress and FDA Clearance for New Clinical Study in Anti-NMDA Receptor Encephalitis Arialys Therapeutics, a clinical-stage biotechnology company focused on developing precision medicines for autoimmune neuropsychiatric disorders, has announced significant clinical and…
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Development of Innovative PTSD Treatment Otsuka America, Inc., a subsidiary of the global healthcare company Otsuka Pharmaceutical Co., Ltd., has completed its acquisition of Transcend Therapeutics, Inc., a biotechnology company focused on…
Gilead Sciences Donates More Than 2,000 Vials of Remdesivir to Support Uganda’s Ebola Bundibugyo Outbreak Response Gilead Sciences has announced the donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda as part…
Paragon Biosciences Completes Sale of Emalex Biosciences to Teva, Marking Another Milestone in CNS Drug Innovation Paragon Biosciences has announced the successful completion of the sale of Emalex Biosciences to Teva Pharmaceutical Industries, a transaction that highlights Paragon’s strategy of…
BeOne Medicines Highlights Long-Term BRUKINSA Benefits in Older CLL Patients at EHA 2026 BeOne Medicines Ltd., a global oncology company dedicated to advancing innovative cancer therapies, has announced the presentation of significant new clinical and real-world evidence supporting the long-term…